Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Financial Lp Hrt Sells 18,531 Shares

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $3.52, for a total transaction of $65,229.12. Following the sale, the insider directly owned 52,274 shares in the company, valued at $184,004.48. This trade represents a 26.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, July 7th, Financial Lp Hrt sold 10,580 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.33, for a total transaction of $35,231.40.
• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.51, for a total value of $31,667.22.
• On Thursday, July 2nd, Financial Lp Hrt purchased 7,851 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average price of $3.54 per share, for a total transaction of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt purchased 3,959 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average cost of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt acquired 6,755 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average price of $3.23 per share, for a total transaction of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average cost of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Trading Down 8.1%

SHPH stock opened at $3.28 on Friday. The firm has a 50 day simple moving average of $5.15 and a 200-day simple moving average of $10.18. The company has a market capitalization of $2.09 million, a P/E ratio of -0.07 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a twelve month low of $2.90 and a twelve month high of $55.90.

Analyst Ratings Changes

SHPH has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday, July 4th. Weiss Ratings upgraded Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Shuttle Pharmaceuticals has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Connective Capital Management LLC bought a new stake in shares of Shuttle Pharmaceuticals during the 3rd quarter valued at about $357,000. Geode Capital Management LLC acquired a new position in Shuttle Pharmaceuticals in the fourth quarter valued at approximately $26,000. Boothbay Fund Management LLC acquired a new position in Shuttle Pharmaceuticals in the fourth quarter valued at approximately $37,000. Finally, Ikarian Capital LLC bought a new position in shares of Shuttle Pharmaceuticals during the fourth quarter valued at approximately $124,000. 4.58% of the stock is owned by institutional investors and hedge funds.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .